Myriad Genetics Inc. has a new significant shareholder disclosure from Glenview Capital Management and its CEO Larry Robbins. As of January 12, 2026, they may be deemed to beneficially own 4,941,058 shares of Myriad Genetics common stock, representing approximately 5.3% of the shares outstanding.
The position is held across three Glenview-managed vehicles: 1,886,965 shares for Glenview Capital Master Fund, 2,791,657 shares for Glenview Offshore Opportunity Master Fund, and 262,436 shares for Glenview Healthcare Master Fund. Glenview and Robbins report shared voting and dispositive power over all 4,941,058 shares, with no sole voting or dispositive power. They also certify that the shares were not acquired to change or influence control of Myriad Genetics.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MYRIAD GENETICS INC
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
62855J104
(CUSIP Number)
01/06/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
62855J104
1
Names of Reporting Persons
GLENVIEW CAPITAL MANAGEMENT, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,941,058.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,941,058.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,941,058.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
62855J104
1
Names of Reporting Persons
ROBBINS LARRY
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,941,058.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,941,058.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,941,058.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IN, HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
MYRIAD GENETICS INC
(b)
Address of issuer's principal executive offices:
322 North 2200 West, Salt Lake City, Utah, 84116
Item 2.
(a)
Name of person filing:
This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):
i. Glenview Capital Management, LLC ("Glenview Capital Management")
ii. Larry Robbins ("Mr. Robbins").
This Statement relates to shares of Common Stock, par value $0.01 per share ("Shares") held for the accounts of Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Capital Master Fund"), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Offshore Opportunity Master Fund"), and Glenview Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("Glenview Healthcare Master Fund").
Glenview Capital Management serves as investment manager to each of Glenview Capital Master Fund, Glenview Offshore Opportunity Master Fund and Glenview Healthcare Master Fund. Mr. Robbins is the Chief Executive Officer of Glenview Capital Management.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 520 Madison Avenue, 33rd Floor, New York, New York 10022.
(c)
Citizenship:
i. Glenview Capital Management is a Delaware limited liability company
ii. Mr. Robbins is a citizen of the United States of America.
(d)
Title of class of securities:
Common Stock, par value $0.01 per share
(e)
CUSIP No.:
62855J104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of January 12, 2026, each of the Reporting Persons may be deemed the beneficial owner of 4,941,058 Shares. This amount consists of: (A) 1,886,965 Shares held for the account of Glenview Capital Master Fund; (B) 2,791,657 Shares held for the account of Glenview Offshore Opportunity Master Fund; and (C) 262,436 Shares held for the account of Glenview Healthcare Master Fund.
(b)
Percent of class:
As of January 12, 2026, each of the Reporting Persons may be deemed the beneficial owner of approximately 5.30% of the Shares outstanding. (There were 93,213,722 Shares outstanding as of October 31, 2025, based on the Issuer's quarterly report on Form 10-Q filed on November 4, 2025.)
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,941,058.00
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,941,058.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See disclosure in Item 2 hereof.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
GLENVIEW CAPITAL MANAGEMENT, LLC
Signature:
/s/ Mark J. Horowitz
Name/Title:
Mark J. Horowitz, Co-President
Date:
01/13/2026
ROBBINS LARRY
Signature:
/s/ Mark J. Horowitz
Name/Title:
Mark J. Horowitz, attorney-in-fact for Larry Robbins
Date:
01/13/2026
Exhibit Information
Exhibit 1: Joint Filing Agreement
Exhibit 2: Power of Attorney
What stake does Glenview Capital report in Myriad Genetics (MYGN)?
As of January 12, 2026, Glenview Capital Management and Larry Robbins may be deemed to beneficially own 4,941,058 shares of Myriad Genetics, representing about 5.3% of the common stock.
Who are the reporting persons in this Myriad Genetics (MYGN) Schedule 13G?
The reporting persons are Glenview Capital Management, LLC, a Delaware limited liability company, and Larry Robbins, its Chief Executive Officer and a U.S. citizen.
How is Glenview’s Myriad Genetics (MYGN) position allocated across its funds?
The 4,941,058 shares consist of 1,886,965 shares for Glenview Capital Master Fund, 2,791,657 shares for Glenview Offshore Opportunity Master Fund, and 262,436 shares for Glenview Healthcare Master Fund.
What level of voting and dispositive power does Glenview have over Myriad Genetics (MYGN) shares?
Glenview Capital Management and Larry Robbins report 0 shares with sole voting or dispositive power and 4,941,058 shares with shared voting and shared dispositive power.
How was the 5.3% ownership in Myriad Genetics (MYGN) calculated?
The approximately 5.3% ownership is based on 93,213,722 shares outstanding of Myriad Genetics common stock as of October 31, 2025, as referenced from the company’s Form 10-Q.
Is Glenview seeking to influence control of Myriad Genetics (MYGN)?
The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Myriad Genetics, other than activities solely in connection with a nomination under Rule 240.14a-11.
